Healthcare
Electromed, Inc.(ELMD)
Live Price
Offline$37.14
-1.25% today
1Y Change
+75.86%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $210.00M
- Revenue Growth
- +17.0%
- EPS Growth
- +50.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Electromed, Inc. (ELMD) is a Healthcare stock with a market cap of $210.00M and listed on AMEX. The stock last traded around $37.14 and up 75.9% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +17.0%, EPS growth of +50.0%, a dividend yield of 0.0%. What stands out right now is revenue +17.0%, EPS +50.0%, free cash flow +27.8% with operating margin 16.7% and ROIC 18.9%. Valuation is more restrained than many high-expectation growth names at P/E 23.7 and price/sales 3.1. Stock Foundry combines ELMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+17.0% vs +7.6% peer median
Operating Margin
Below sector median
+16.7% vs +19.4% peer median
P/E
Below sector median
23.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +17.0% and EPS at +50.0%, with operating margin around 16.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +9.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +25.1% | +41.1% | +36.7% |
2026 Feb 10, 2026 | +18.5% | -10.0% | -11.6% | -15.0% |
2025 Nov 12, 2025 | +13.6% | +3.8% | -0.7% | +16.4% |
Benchmark Edge
ELMD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ELMD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ELMD Max Drawdown
-23.27%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ELMD and SPY.
Company Overview
Electromed, Inc.
New York Stock Exchange American
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
- Leadership
- James L. Cunniff
- IPO Date
- Aug 13, 2010
- Employees
- 174
- Street Address
- 500 Sixth Avenue NW
- Mailing
- New Prague, MN, 56071
- Region
- New Prague, MN, US
- Reporting Currency
- USD
- Investor Line
- 952 758 9299
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 23.7
- EV/EBITDA
- 15.7
- Price/Sales
- 3.1
- Price/Book
- 4.7
Growth
- Revenue
- +17.0%
- EPS
- +50.0%
- Free Cash Flow
- +27.8%
Profitability
- Gross Margin
- 78.2%
- Operating Margin
- 16.7%
- Net Margin
- 13.1%
- ROE
- 20.3%
- ROIC
- 18.9%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 4.86
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.